Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.

Ann Med · 2021 · PMC8409966 · PMID 34459681

Europe PMC DOI

hedged sentence

0.1780

closest p · 3.6× alpha

0.1780

boldest claim

The sentences

showed a trendp = 0.178not close (p > 0.1)

High dose group showed a trend to have higher incidence of grade 3–4 CRS than low dose group without reaching a statistical significance (8.4%, 95%CI −0.009–0.177; I 2 = 34.5%, p = 0.178 vs 1.6%, 95%CI −0.026–0.058; I 2 = 0.0%, p = .939) ( z = 1.53, P = .127) ( Figure 9(C) ). 3.4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.